Integer Holdings Corp ITGR
We take great care to ensure that the data presented and summarized in this overview for Integer Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ITGR
View all-
Black Rock Inc. New York, NY5.39MShares$654 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.83MShares$465 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.99MShares$242 Million0.06% of portfolio
-
Franklin Resources Inc San Mateo, CA1.56MShares$190 Million0.06% of portfolio
-
State Street Corp Boston, MA1.3MShares$157 Million0.01% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.23MShares$149 Million0.63% of portfolio
-
Earnest Partners LLC Atlanta, GA1.17MShares$142 Million0.64% of portfolio
-
Macquarie Group LTD Australia, C31.01MShares$123 Million0.14% of portfolio
-
Victory Capital Management Inc1MShares$122 Million0.12% of portfolio
-
Invesco Ltd. Atlanta, GA966KShares$117 Million0.02% of portfolio
Latest Institutional Activity in ITGR
Top Purchases
Top Sells
About ITGR
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Insider Transactions at ITGR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 24
2024
|
James F. Hinrichs |
SELL
Open market or private sale
|
Direct |
9,603
-56.4%
|
$1,171,566
$122.44 P/Share
|
May 24
2024
|
James F. Hinrichs |
BUY
Exercise of conversion of derivative security
|
Direct |
9,603
+24.12%
|
$422,532
$44.6 P/Share
|
May 22
2024
|
Cheryl C Capps Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,480
+14.7%
|
-
|
May 22
2024
|
Martin C Maxwell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,480
+5.52%
|
-
|
May 22
2024
|
Filippo Passerini Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,480
+5.08%
|
-
|
May 22
2024
|
Sheila Antrum Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,480
+14.7%
|
-
|
May 15
2024
|
Jim Stephens President, CRM & Neuro |
SELL
Payment of exercise price or tax liability
|
Direct |
120
-24.49%
|
$14,040
$117.72 P/Share
|
May 15
2024
|
Jim Stephens President, CRM & Neuro |
BUY
Exercise of conversion of derivative security
|
Direct |
490
+50.0%
|
-
|
May 10
2024
|
Payman Khales President, C&V |
SELL
Open market or private sale
|
Direct |
8,712
-45.51%
|
$984,456
$113.84 P/Share
|
May 08
2024
|
Diron Smith EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
503
-17.52%
|
$56,839
$113.14 P/Share
|
May 08
2024
|
Diron Smith EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,062
+41.8%
|
-
|
May 07
2024
|
Andrew Senn SVP, Strategy and Business Dev |
SELL
Open market or private sale
|
Direct |
5,000
-27.36%
|
$565,000
$113.56 P/Share
|
May 07
2024
|
John A Harris EVP, Global Ops and Manufactur |
SELL
Open market or private sale
|
Direct |
312
-21.24%
|
$35,256
$113.0 P/Share
|
Apr 30
2024
|
Tommy P Thomas VP, Corporate Controller |
SELL
Open market or private sale
|
Direct |
1,500
-34.78%
|
$171,000
$114.0 P/Share
|
Feb 22
2024
|
Kirk K Thor Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,121
-9.81%
|
$212,100
$100.18 P/Share
|
Feb 22
2024
|
Kirk K Thor Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,302
+27.75%
|
-
|
Feb 22
2024
|
Margaret Carthy EVP, Qlty & Regulatory Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
853
-14.32%
|
$85,300
$100.18 P/Share
|
Feb 22
2024
|
Margaret Carthy EVP, Qlty & Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,640
+21.59%
|
-
|
Feb 22
2024
|
Joseph W Dziedzic President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,821
-12.18%
|
$3,082,100
$100.18 P/Share
|
Feb 22
2024
|
Joseph W Dziedzic President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
78,324
+23.63%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 111K shares |
---|---|
Exercise of conversion of derivative security | 58.7K shares |
Open market or private sale | 35.3K shares |
---|---|
Payment of exercise price or tax liability | 52.5K shares |